← All trials
NCT05431725
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Jul 14, 2022
- Primary completion
- May 31, 2023
- Completion date
- Jul 31, 2023
- First posted
- Jun 24, 2022
- Last posted
- Aug 26, 2022
- Enrollment
- 1600
- Arms / groups
- 2 / —
- Source
- AACT · ctgov ingestion
Sponsors
- Sinovac Biotech Co., LtdLead sponsor
- Sinovac Biotech Co., LtdCollaborator
- Pontificia Universidad Catolica de ChileCollaborator
- Pontificia Universidad Catolica de ChileOverall official - principal investigator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.